Epigenomics AG

  • WKN: A11QW5
  • ISIN: DE000A11QW50
  • Land: Deutschland

Nachricht vom 07.11.2018 | 10:13

Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG

07.11.2018 / 10:13
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Name: Epigenomics AG
Street: Geneststraße 5
Postal code: 10829
City: Berlin
Germany
Legal Entity Identifier (LEI): 549300X1C4U862NDLN97

2. Reason for notification
X Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
  Other reason:

3. Details of person subject to the notification obligation
Natural person (first name, surname): Roberto Mignone
Date of birth: 22 Aug 1971

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
Bridger Healthcare Ltd.

5. Date on which threshold was crossed or reached:
29 Oct 2018

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 3.75 % 0 % 3.75 % 36021540
Previous notification n/a % n/a % n/a % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE000A11QW50 0 1350000 n/a % 3.75 %
Total 1350000 3.75 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
%
    Total %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
%
      Total %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
Mr. Roberto Mignone % % %
Bridger Management LLC 3.75 % % %
 
Mr. Roberto Mignone % % %
Bridger Capital LLC % % %
Bridger EMP LLC / Shearwater Onshore LLC % % %
Bridger Healthcare Ltd. 3.75 % % %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
 

Date
06 Nov 2018



07.11.2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

UniDevice AG: Rekord-Ergebnis in 2018

Nach starkem Schlussspurt hat die UniDevice AG in 2018 Umsatz und Ergebnis deutlich gesteigert. Der B2B-Broker für hochpreisige Smartphones sollte auch künftig eine hohe Nachfrage verzeichnen und von der Ausnutzung unterschiedlicher Preisniveaus in den verschiedenen Ländern profitieren. Der Umsatz soll 2019 auf mindestens 380 Mio. € und in 2020 auf mindestens 410 Mio. € ansteigen, nachdem 2018 317 Mio. € erreicht wurden. Bei einem ermittelten Kursziel in Höhe von 2,35 € lautet das Rating KAUFEN.

News im Fokus

Linde plc: Linde plc Investor & Media Conference Call - Information

22. Februar 2019, 19:38

Aktueller Webcast

Ströer SE & Co. KGaA

Vorläufige Geschäftszahlen 2018

26. Februar 2019

Aktuelle Research-Studie

Sanochemia Pharmazeutika AG

Original-Research: Sanochemia Pharmazeutika AG (von Sphene Capital GmbH): Buy

21. Februar 2019